cellvie Inc.
cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 2018
- Employees:
- 1-10
About Us
Committed to Advance Medicine
At cellvie, we believe in the power of cell-derived medicines. We are dedicated to bring about nothing short of a new treatment modality, to safe and improve the lives of patients in need. We take joy from and pride in facing the challenge of advancing medicine.
Cellvie's Greatest Asset
A medicinal invention is only as meaningful as the products it spurs that reach patients in need. To turn Therapeutic Mitochondria Transplantation from an approach to a platform of products takes a team of individuals spellbound to realize the technology's potential. At cellvie, we have come together as such a group of like-minded experts from the fields of science, regulatory, manufacturing and business. We are passionate about our technology and the problems we are solving. We take pride in and joy from this work and are going the extra mile, so Therapeutic Mitocondria Transplantation reaches patients in need.
Welcome
At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism. We are deriving medicines from cells, leveraging one of the cornerstones of evolution: mitochondria.
Mitochondria are the powerhouses of the cell. cellvie is employing Therapeutic Mitochondria Transplantation, a technique of augmentation and replacement to reinvigorate the cell energy metabolism when the mitochondria are failing. The first application will be in ischemia-reperfusion injury, the world's number 1 killer.
Mitochondria are membrane-bound cell organelles that generate most of the energy needed to power the cell's biochemical reactions. In a process referred to as symbiogenesis, mitochondria are said to have merged with a simple cellular organism, giving rise to complex life and its evolution. In this process, Mitochondria took over vital roles within the cell, including:
cellvie is targeting ischemia-reperfusion injury as its technology's first application. Ischemia-Reperfusion is a ubiquitous challenge, arising whenever blood flow is interrupted and subsequently re-introduced. Medical conditions giving rise to ischemia-reperfusion injury are heart attacks, stroke, long surgical procedures and organ transplantation.
The first indication will be in kidney transplantation. With 12 patients dying each day waiting for a kidney, the need is particularly dear. The aim is to reduce the incidence of delayed graft function, which arises in up to 50% of kidney recipients.
With mitochondria a common denominator in health as well as in disease and aging, cellvie strives to bring about Therapeutic Mitochondria Transplantation as a novel category of medicines. The approach's ability to sustainably affect the cell-energy-metabolism opens new avenues to treat hitherto intractable human conditions.
Beyond ischemia-reperfusion injury, the team at cellvie is particularly interested in the technology's application to slow or reverse degenerative processes of aging linked to the mitochondria.